Corporate Overview

We are a global medical technology company focused on the development and commercialization of our proprietary Vapotherm high velocity therapy, a tool used to treat patients of all ages suffering from respiratory distress. High velocity therapy delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Our Precision Flow systems, which deliver high velocity therapy, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress in a hospital setting. More than 4 million patients have been treated with our Precision Flow systems, and we have a global installed base of over 37,000 capital units. 

Latest News
02/22/2024

Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2023 financial results and related highlights. Fourth Quarter 2023 Financial Results...

READ MORE

12/14/2023

Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence...

READ MORE

12/11/2023

Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and its filing of an...

READ MORE

VIEW ALL NEWS

Latest Presentation

12/19/2023

Vapotherm Company Overview

VIEW ALL PRESENTATIONS

Latest Events
No events to display

VIEW ALL EVENTS

Latest Quarterly Reports